IVVD - NASDAQ

Invivyd, Inc.

Invivyd, Inc.

IVVDยทNASDAQ

$1.14

+1.5%
HealthcareBiotechnology

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$151.31M
EPS-0.3000
P/E Ratio-8.10
Earnings Date08/13/2026
Invivyd, Inc.

Invivyd, Inc. Fair Value Envelope

IVVD ยท NASDAQ

Our analysis suggests that IVVD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.14, this represents a potential HIDDEN relative to our calculated worth for Invivyd, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.14

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$12.0B
+ Cash & Equivalents$226.7M
Firm Value-$11.8B
- Debt$2.5M
Equity Value-$11.8B
/ Shares Outstanding119,948,453B
DCF Value-$98
OVERVALUED BY 8703%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$96.4M
-$159.9M
-$265.2M
-$439.7M
-$729.2M
-$1.2B
-$2.0B
-$3.3B
-$5.5B
-$9.1B
Maintenance CapEx
-$51.4K
-$85.3K
-$141.4K
-$234.5K
-$388.9K
-$644.9K
-$1.1M
-$1.8M
-$2.9M
-$4.9M
Owner Earnings
-$96.5M
-$160.0M
-$265.3M
-$440.0M
-$729.6M
-$1.2B
-$2.0B
-$3.3B
-$5.5B
-$9.2B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$89.3M
-$137.1M
-$210.6M
-$323.4M
-$496.6M
-$762.5M
-$1.2B
-$1.8B
-$2.8B
-$4.2B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your IVVD research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.